Skip to main content

Table 2 Baseline characteristics of patients, stratified by presence of mechanical valves

From: Cardiac implantable electronic device surgery with interruption of warfarin forgoing post-operative bridging therapy in patients with moderate or high thromboembolic risks

  All patients Mechanical valve No mechanical valve
N = 411 N = 257 N = 154
Indication for warfarin therapy - no. (%)
 Mechanical heart valve replacement (any) 257 62.5% 257 100.0%   
 Mechanical mitral valve replacement 212 51.3% 212 82.5%   
 Mechanical aortic valve replacement 121 29.0% 121 47.1%   
 Mitral stenosis (native valve) 13 3.2%    13 8.4%
 Atrial fibrillation or atrial flutter 318 77.4% 186 72.4% 132 85.7%
 CHAD2S2-VASc (for non-valvular AF; N = 119) - mean ± S.D.      3.34 ± 1.93
 CHAD2S2-VASc ≥2 (for non-valvular AF; N = 119)      96 80.7%
 Deep vein thrombosis or pulmonary embolism 4 1.0% 0 0.0% 4 2.6%
 Intracardiac thrombus 14 3.4% 0 0.0% 14 9.1%
Medications - no. (%)
 Any anti-platelet therapy 69 16.8% 20 7.8% 49 31.8%
 Aspirin 68 16.6% 20 7.8% 48 31.2%
 P2Y12 inhibitor 5 1.2% 1 0.4% 4 2.6%
 Statin 153 37.2% 78 30.4% 75 48.7%
 ACE inhibitor or ARB 215 52.3% 117 45.5% 98 63.6%
 Beta-blocker 220 53.5% 118 45.9% 102 66.2%
 Diuretics 312 75.9% 196 76.3% 116 75.3%
 Pre-operative low molecular weight heparin 235 57.2% 181 70.4% 54 35.0%
  1. Abbreviations: S.D. standard deviation, ACE angiotensin converting enzyme, ARB angiotensin receptor blocker